EC Number |
Inhibitors |
Structure |
---|
2.7.8.27 | 1-methylcyclopropyl 4-(3-((3-((3,5-bis(trifluoromethyl)benzyl)(methyl)carbamoyl)-1-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl)oxy)propyl)piperidine-1-carboxylate |
inhibitor of isoform SGMS2 with good selectivity against SGMS1 |
|
2.7.8.27 | 1-methylcyclopropyl 4-(3-((3-((3,5-bis(trifluoromethyl)benzyl)(methyl)carbamoyl)-1-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl)oxy)propyl)piperidine-1-carboxylate |
- |
|
2.7.8.27 | 1-methylcyclopropyl 4-(3-((3-((3,5-bis(trifluoromethyl)benzyl)(methyl)carbamoyl)-1-methyl-2-oxo-1,2-dihydroquinolin-4-yl)oxy)propyl)piperidine-1-carboxylate |
150fold selectivity for isoform SGMS2 over SGMS1; 150fold selectivity for isoform SGMS2 over SGMS1. The interaction with SGMS2 requires the presence of the amino acids S227 and H229, which are located in the catalytic domain of SMS2 |
|
2.7.8.27 | 1-methylcyclopropyl 4-(3-((3-((3-methoxy-5-(trifluoromethyl)benzyl)(methyl)carbamoyl)-1-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl)oxy)propyl)piperidine-1-carboxylate |
inhibitor of isoform SGMS2 with good selectivity against SGMS1; potent and selective inhibitor of isoform SGMS2. A repeated treatment in mice leads to significant reduction in hepatic sphingomyelin levels |
|
2.7.8.27 | 1-methylcyclopropyl 4-(3-((3-((3-methoxy-5-(trifluoromethyl)benzyl)(methyl)carbamoyl)-1-methyl-2-oxo-1,2-dihydro-1,8-naphthyridin-4-yl)oxy)propyl)piperidine-1-carboxylate |
- |
|
2.7.8.27 | 2-((2,5-dichlorobenzyl)oxy)-N-(pyridin-3-yl)benzamide |
- |
|
2.7.8.27 | 2-((2,5-dimethoxybenzyl)oxy)-N-(pyridin-3-yl)benzamide |
- |
|
2.7.8.27 | 2-((2,6-dichlorobenzyl)oxy)-N-(pyridin-3-yl)benzamide |
- |
|
2.7.8.27 | 2-((2,6-dimethylbenzyl)oxy)-N-(pyridin-3-yl)benzamide |
- |
|
2.7.8.27 | 2-((2-((5-chloropentyl)oxy)benzyl)oxy)-N-(pyridin-3-yl)benzamide |
- |
|